<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82411">
  <stage>Registered</stage>
  <submitdate>13/11/2007</submitdate>
  <approvaldate>20/11/2007</approvaldate>
  <actrnumber>ACTRN12607000596404</actrnumber>
  <trial_identification>
    <studytitle>Zometa as a prophylactic treatment for bone mineral density loss in cancer patients following allogeneic stem cell transplantation</studytitle>
    <scientifictitle>A treatment algorithm evaluating the effect of zoledronic acid on bone mineral density loss after allogeneic stem cell transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BM07 - Australasian Leukaemia and Lymphoma Group Trial Number</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Loss of bone mineral density in cancer patients whom have undergone allogeneic stem cell transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Zoledronic acid.  4mg dose administered intravenously.  Dosing will occur in all patients within 7-days prior to the commencement of the conditioning regimen prior to stem cell transplantation, Zoledronic acid dosing will also occur following transplant at 3, 6, and 9 months if required.</interventions>
    <comparator>The comparator is no treatment.  A historical group that did not receive prophylactic treatment for bone density loss while undergoing allogeneic stem cell transplantation will be used as controls.</comparator>
    <control>Historical</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent change in bone mineral density compared to baseline</outcome>
      <timepoint>at day 100 and day 365 following allogeneic stem cell transplantation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A comparison of bone mineral density with historical controls</outcome>
      <timepoint>12-months post-alloSCT</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients agend 18 years or over undergoing allogeneic stem cell transplantation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Eastern Cooperative Oncology Group (ECOG) performace status &gt;1</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress>C- Centre for Biostatistics and Clinical Trials
Peter MacCallum Cancer Centre
East Melbourne VIC 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals Australia</fundingname>
      <fundingaddress>54 Waterloo Road, North Ryde, NSW, 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A side-effect of allogeneic stem cell transplantation is a big loss in bone strength.  Bone-strength is also called bone mineral density (BMD).  One of the problems with a loss in bone strength is a higher risk of osteoporosis and bone fractures later in life.  Hence, we are keen to look at ways by which this loss in bone-strength can be minimised.
A group of drugs, called bisphosphonates, have been shown to reduce the rate of bone-strength loss after transplants.  The current study is a follow-on study that will will use a newer and more powerful bisphosphonate drug called zoledronic acid or Zometa®.  Zometa® will be given to all patients before transplant but after transplant it will only be given to those patients whose bone mineral density (BMD) scan shows a &gt;3% loss of bone density or to patients who receive large doses of prednisolone (steroid therapy).  The aim is to use Zometa® only when it is needed.
The main measure of the success of the study is whether we can stop bone density loss, which will be calculated by comparing the results of the pre-transplant scan with those from the scans at day 100 and 12 months after the transplant.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Andrew Grigg</name>
      <address>Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427690</phone>
      <fax />
      <email>andrew.grigg@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Andrew Grigg</name>
      <address>Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427690</phone>
      <fax />
      <email>andrew.grigg@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>